Royal Philips Strengthens Image Guided Therapy Offering Through SpectraWAVE Acquisition

Posted on 15, December 2025 by | This entry was posted in Artificial Intelligence (AI), Business, Electronics & Machinery, Healthcare, Investment, Management, Netherlands, News, Science, Technology and tagged , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Royal Philips Strengthens Image Guided Therapy Offering Through SpectraWAVE Acquisition

(IN BRIEF) Royal Philips has entered into an agreement to acquire SpectraWAVE, adding AI-powered intravascular imaging and angiography-based physiology technologies to its coronary intervention portfolio. The acquisition expands Philips’ offering with SpectraWAVE’s HyperVue Imaging System and X1-FFR, complementing existing IVUS and iFR solutions and strengthening integration with the Azurion image-guided therapy platform. The move supports broader adoption of advanced imaging and physiology tools for percutaneous coronary interventions, aiming to improve clinical decision-making, efficiency and patient outcomes. Financial terms were not disclosed.

(PRESS RELEASE) AMSTERDAM, 15-Dec-2025 — /EuropaWire/ — Royal Philips (NYSE: PHG, AEX: PHIA), has announced an agreement to acquire SpectraWAVE, Inc., strengthening its position in coronary intervention with the addition of next-generation intravascular imaging and physiology technologies powered by artificial intelligence. The acquisition brings SpectraWAVE’s HyperVue Imaging System, featuring Enhanced Vascular Imaging that combines DeepOCT and near-infrared spectroscopy, alongside X1-FFR, an AI-enabled angiography-based fractional flow reserve solution that delivers rapid coronary physiology assessment from a single angiogram.

Clinician and patient with Azurion and IntraSight

The transaction expands Philips’ existing intravascular imaging and physiological assessment portfolio, which already includes Eagle Eye Platinum digital IVUS and OmniWire iFR technology. Together, these solutions are designed to create a comprehensive, integrated offering for clinicians performing percutaneous coronary interventions, enabling more informed decision-making, streamlined workflows and improved patient outcomes. When combined with Philips’ Azurion image-guided therapy platform, the expanded portfolio is expected to support broader adoption of advanced imaging and physiology tools in daily clinical practice.

SpectraWAVE’s technologies address key challenges in the treatment of coronary artery disease, the most common form of heart disease globally. The HyperVue Imaging System provides detailed structural and compositional views of coronary arteries with rapid setup and automated AI-supported analysis, while X1-FFR transforms standard angiographic images into actionable physiology data without the need for a pressure wire. This approach supports faster, more efficient procedures while maintaining diagnostic accuracy.

DeepOCT Enhanced Vascular Imaging

Philips continues to invest in minimally invasive image-guided therapy, an area supported by growing clinical evidence showing improved outcomes and cost effectiveness when intravascular imaging and physiological assessment are used to guide coronary interventions. The acquisition reflects Philips’ strategy to integrate hardware, software and AI into a unified platform that allows clinicians to decide, guide, treat and confirm therapy within a single procedural environment.

SpectraWAVE, founded in 2017 and headquartered in Bedford, Massachusetts, employs more than 70 people and has focused on advancing AI-driven solutions for coronary imaging and physiology. Financial terms of the agreement were not disclosed.

Sources

[1] The SpectraWAVE HyperVue Imaging System and the Starlight Imaging Catheter is a US Class 2 device cleared by FDA through K221257 and K230691. The SpectraWAVE X1-FFR Software is a US Class 2 device cleared by FDA through K251355.
[2] Compared with angiography-guided Percutaneous Coronary Interventions.
[3] AI-derived algorithms are deployed on the device to support vessel segmentation and contouring. Analytical (non-AI) models are used for generating FFR values.
[4] Stark, B., Johnson, C., & Roth, G. A. (2024). Global prevalence of coronary artery disease: An update from the Global Burden of Disease Study. Journal of the American College of Cardiology, 83(13 Suppl), 2320. https://doi.org/10.1016/S0735-1097(24)04310-9
[5] Mandurino-Mirizzi, A., Munafò, A. R., Rizzo, F., De Francesco, R., Raone, L., Germinal, F., Montalto, C., Mussardo, M., Moci, M., Vergallo, R., Rocco, V., Fischetti, D., Dionigi, F., Godino, C., Colonna, G., Oreglia, J., Burzotta, F., Crimi, G., & Porto, I. (2025). Comparison of different guidance strategies to percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. International Journal of Cardiology, 422, 132936. https://doi.org/10.1016/j.ijcard.2024.132936
[6] Stone, G. W., Christiansen, E. H., Ali, Z. A., Andreasen, L. N., Maehara, A., Ahmad, Y., Landmesser, U., & Holm, N. R. (2024). Intravascular imaging-guided coronary drug-eluting stent implantation: An updated network meta-analysis. The Lancet, 403(10429), 824–837. https://doi.org/10.1016/S0140-6736(23)02454-6
[7] Gaster, A. L., Slothuus Skjoldborg, U., Larsen, J., Korsholm, L., von Birgelen, C., Jensen, S., Thayssen, P., Pedersen, K. E., & Haghfelt, T. H. (2003). Continued improvement of clinical outcome and cost effectiveness following intravascular ultrasound guided PCI: Insights from a prospective, randomized study. Heart, 89(9), 1043–1049. https://doi.org/10.1136/heart.89.9.1043

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other important information

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Media Contact:

Michael Fuchs
Philips Global External Relations
Contact details
Tel: +31614869261
media@philips.com

Dorin Danu
Philips Investor Relations
Contact details
Tel: +31205977055
dorin.danu@philips.com

SOURCE: Philips

MORE ON PHILIPS, ETC.:

EDITOR'S PICK:

Comments are closed.